Moderna, Inc. Common Stock (MRNA) Stock Price

MRNAStockS&P 500

$218.01+703.28%52W

Market Cap$87.04B

P/E—

PEG Ratio—

Div yield—

Beta1.17

MRNA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)302.68%

Price vs S&P 500 (4W)27.39%

VGM Score52.57

Book Value / Share (Quarterly)$16.94

P/TBV (Annual)1.34x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-53.44%

Cash Flow / Share (Quarterly)$-3.12

Price vs S&P 500 (YTD)627.34%

Gross Margin (TTM)36.40%

Net Profit Margin (TTM)-141.43%

EPS (TTM)$-7.98

10-Day Avg Trading Volume20.07M

EPS Excl Extra (TTM)$-7.98

Revenue Growth (5Y)19.34%

EPS (Annual)$-7.25

ROI (Annual)-30.39%

Gross Margin (Annual)70.32%

Net Profit Margin (5Y Avg)-42.91%

Cash / Share (Quarterly)$12.88

Revenue Growth QoQ (YoY)2.11%

ROA (Last FY)-22.87%

Revenue Growth TTM (YoY)-27.62%

EBITD / Share (TTM)$-7.82

ROE (5Y Avg)6.13%

Operating Margin (TTM)-149.01%

Cash Flow / Share (Annual)$-5.27

P/B Ratio12.87x

P/B Ratio (Quarterly)4.11x

Net Income / Employee (Annual)$-600,400

EV / Revenue (TTM)38.57x

ROA (TTM)-26.86%

EV / EBITDA (TTM)98.11x

EPS Incl Extra (Annual)$-7.25

Current Ratio (Annual)3.29x

Quick Ratio (Quarterly)2.08x

3-Month Avg Trading Volume16.22M

52-Week Price Return703.28%

EV / Free Cash Flow (Annual)2.54x

Revenue / Employee (TTM)$474,000

Tangible BV / Share (Quarterly)$16.67

P/S Ratio (Annual)44.77x

Asset Turnover (Annual)0.16x

52-Week High$242.29

Operating Margin (5Y Avg)-44.21%

EPS Excl Extra (Annual)$-7.25

CapEx CAGR (5Y)24.70%

Tangible BV CAGR (5Y)98.20%

26-Week Price Return312.59%

Quick Ratio (Annual)3.08x

13-Week Price Return252.65%

Total Debt / Equity (Annual)0.07x

Current Ratio (Quarterly)2.29x

Enterprise Value$85.94B

Revenue / Share Growth (5Y)18.85%

Asset Turnover (TTM)0.19x

Book Value / Share Growth (5Y)27.87%

Revenue / Employee (Annual)$413,600

Inventory Turnover (Annual)4.27x

Pretax Margin (Annual)-142.39%

Cash / Share (Annual)$14.72

3-Month Return Std Dev359.71%

Gross Margin (5Y Avg)72.34%

Net Income / Employee (TTM)$-670,400

ROE (Last FY)-32.62%

EPS Basic Excl Extra (Annual)$-7.25

P/FCF (TTM)97.69x

Receivables Turnover (TTM)84.08x

Total Debt / Equity (Quarterly)0.09x

EPS Incl Extra (TTM)$-7.98

Receivables Turnover (Annual)7.17x

ROI (TTM)-36.96%

P/S Ratio (TTM)39.07x

Pretax Margin (5Y Avg)-37.96%

Revenue / Share (Annual)$5.00

Tangible BV / Share (Annual)$21.84

Price vs S&P 500 (52W)687.75%

Year-to-Date Return639.27%

5-Day Price Return2.00%

EPS Normalized (Annual)$-7.25

ROA (5Y Avg)1.63%

Net Profit Margin (Annual)-145.16%

Month-to-Date Return13.21%

Cash Flow / Share (TTM)$-7.54

EBITD / Share (Annual)$-7.35

Operating Margin (Annual)-158.13%

LT Debt / Equity (Annual)0.07x

ROI (5Y Avg)5.54%

LT Debt / Equity (Quarterly)0.09x

EPS Basic Excl Extra (TTM)$-7.98

P/TBV (Quarterly)4.18x

P/B Ratio (Annual)1.33x

Inventory Turnover (TTM)5.45x

Pretax Margin (TTM)-138.55%

Book Value / Share (Annual)$21.95

Price vs S&P 500 (13W)249.97%

Beta1.17x

P/FCF (Annual)19.00x

Revenue / Share (TTM)$5.60

ROE (TTM)-39.20%

52-Week Low$22.28

vGradeF

gGradeC

mGradeA

vgmGradeC

MRNA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 31, 2026	-$2.06	-$1.97	+4.33%(+$0.09)
Q1 2026	May 1, 2026	-$3.88	-$3.40	+12.37%(+$0.48)
Q4 2025	Feb 13, 2026	-$2.60	-$2.11	+18.88%(+$0.49)
Q3 2025	Nov 6, 2025	-$2.18	-$0.51	+76.60%(+$1.67)
Q2 2025	Aug 1, 2025	-$2.97	-$2.13	+28.28%(+$0.84)

MRNA Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

2.80

3.23

3.43

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	B	168.6x	-19.0%	—	—	$17.17

About Moderna, Inc. Common Stock

Moderna is a biotechnology company leveraging its validated mRNA platform to develop therapeutics across infectious disease, oncology, cardiovascular disease, and rare genetic diseases. The company commercially validated its technology with its FDA-authorized COVID-19 vaccine in 2020. As of August 2025, Moderna maintains a pipeline of 35 mRNA candidates in clinical development.